Prednisolone (oral) |
Formulary
|
Tablets 1mg, 5mg First line oral corticosteroid treatment. 25mg tablets are classified as Do Not Prescribe. There is no evidence that e/c prednisolone reduces the risk of gastrointestinal side effects. Uncoated 5mg tablets should be prescribed first line together with a PPI if necessary. |
MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
Budesonide Budenofalk® |
Formulary
|
e/c capsules 3mg First line rectal treatment (foam enema) |
|
Budesonide Kinpeygo® |
Formulary
|
Modified release capsules 4mg (targeted release) For treating primary IgA nephropathy in accordance with NICE TA937 |
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy |
|
Budesonide Cortiment MMX® |
Formulary
|
Tablets, M/R 9 mg |
LSCMMG: Budesonide multimatrix (MMX) |
|